Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: Adjuvant effects of aluminum phosphate and CpG oligodeoxynucleotides
Version of Record online: 4 MAR 2003
Copyright © 2003 Wiley-Liss, Inc.
Journal of Medical Virology
Volume 70, Issue 1, pages 86–90, May 2003
How to Cite
Temperton, N. J., Quenelle, D. C., Lawson, K. M., Zuckerman, J. N., Kern, E. R., Griffiths, P. D. and Emery, V. C. (2003), Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: Adjuvant effects of aluminum phosphate and CpG oligodeoxynucleotides. J. Med. Virol., 70: 86–90. doi: 10.1002/jmv.10357
- Issue online: 4 MAR 2003
- Version of Record online: 4 MAR 2003
- Manuscript Accepted: 30 OCT 2002
- Royal Free Peter Samuel Fund
- University of London Central Research Fund
- Peel Medical Research Trust
- DNA vaccine;
- CpG ODN;
A human cytomegalovirus (HCMV) glycoprotein B (gpUL55) DNA vaccine has been evaluated in BALB/c mice. Intramuscular immunization of these mice with pRc/CMV2-gB resulted in the generation of high levels of gpUL55-specific antibody (geometric mean titer [GMT] 1:8900) and neutralizing antibody (GMT 1:74) after 2 booster doses given 5 and 10 weeks after primary inoculation. Emulsifying the construct with the aluminum phosphate gel adjuvant Adju-Phos before immunization enhanced gpUL55-specific antibody responses (GMT 1:17800, P = 0.04). Co-immunization with CpG oligodeoxynucleotides was shown to enhance levels of neutralizing antibodies generated by immunization of mice with a pRc/CMV2-gB/Adju-Phos emulsion (P = 0.04). The results provide a rationale for evaluating combinations of other HCMV proteins for incorporation into a multi-target DNA vaccine, and for the optimization of adjuvant usage, to elicit enhanced levels of neutralizing antibodies. J. Med. Virol. 70:86–90, 2003. © 2003 Wiley-Liss, Inc.